HIV

Patients treated with HIV therapy less likely to get infected with HBV.

In addition to facing the risk of fatal overdose, kidney disease, and pneumonia, heroin users also have a greater likelihood of acquiring HIV.

Patients treated with HIV therapy less likely to get infected with HBV.

Antiretroviral drug interactions now included due to high prevalence of HIV coinfection among patients with hepatitis C virus.

Specific vaccine-induced immune responses correlate with reduced HIV infection.

Study finds many silver plans have higher out-of-pocket costs for most the commonly prescribed HIV treatments.

HIV drug Tenofovir may carry a risk of nephrotoxicity.

Inspired by her volunteer work at an AIDS foundation, a pharmacy student investigates HIV PEP therapy across 3 continents.

Nanoforumulated protease inhibitor protects HIV drug from being degraded by the liver and removed by the kidney.

Database supports HIV research by increasing sample power and decreasing study biases.

Rectal microbicide formulated as an enema may inhibit the spread of HIV and other sexually transmitted infections.

HIV-1-associated neurocognitive disorders afflict almost half of all patients with HIV.

Gilead's Genvoya is the first TAF-based regimen approved by the FDA.

Guidance addresses the development of clinical trials to test novel antiretroviral drugs for the treatment of HIV.

Altering viral swarm may drive development of antibodies that could neutralize HIV strains.

The use of oral, combined, highly active antiretroviral therapy presents challenges for patients with HIV.

Experts discuss issues faced by patients starting an HIV therapy regimen.

Pharmacists should be asking their patients with HIV not only if they are taking their medications, but also how they are taking them.

Researchers hope new treatment delivery system will reduce administration down to once or twice per year.

Research may improve the diagnosis of infectious and autoimmune diseases, including rheumatoid arthritis and HIV.

Research may offer powerful new tool in the treatment of HIV.

Researchers determine why HIV persists in some patients and remains dormant in others.

Stribild (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) is approved for treatment of HIV-1 infection.

Pharmacy testing could reduce the number of undiagnosed HIV patients and new infections.

HIV patients not on recommended regimens are less likely to achieve viral suppression and more likely to report side effects.